All Activity

One of President Donald Trump’s longtime advisors, Roger Stone, says his administration has an opportunity to move forward with marijuana rescheduling—or, even broader legalization—in a way that Democrats who regularly tout the reform failed to achieve when they controlled the White House and Congress. During a segment of “The Stone Zone” on 77WABC Radio that aired on Monday, Stone responded to Trump’s social media post over the weekend where he shared a video that touted the health benefits of hemp-derived CBD, particular for seniors. “The video posted by President Trump talked about the use of CBD oil to alleviate pain, lower stress and result in better sleep. CBD is the non-psychoactive compound found in cannabis,” Stone said. “It does not get you high, and it is a source of most of the medicinal benefits from the cannabis plant.” He added that it’s well-understood that the president has been a “supporter of states’ rights on the question of the legalization of cannabis for medicinal purposes.” “That has always been his position. Go all the way back to the 2016 campaign,” he said. “I myself have been a major advocate for President Trump reclassifying or declassifying cannabis. Right now, cannabis is considered a Schedule I drug, along with heroin, MDMA and LSD.” While Trump didn’t directly comment on the content of the video he shared over the weekend, he has previously endorsed moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). And he said last month that a decision on that reform would be made within weeks. Stone somewhat misstated the impact of that potential policy change, saying it would “make it allowable for medicinal use” and “also solve a number of the banking issues” for state-licensed cannabis businesses. Will President Trump Reclassify or Declassify Marijuana to Expand Its Legal Medicinal Use? The StoneZONE — Tonight, only on 77WABC Radio! Listen LIVE at 8 PM ET: https://t.co/53a3PGhes4 pic.twitter.com/azS86U7Lje — Roger Stone (@RogerJStoneJr) September 29, 2025 Moving marijuana to Schedule III would remove certain research barriers, but it would need to be approved by the Food and Drug Administration (FDA) to be accessible as a prescribed medicine, which is unlikely in botanical form. And it would let cannabis businesses take federal tax deductions they’ve been barred from under an Internal Revenue Service (IRS) code known as 280E, but since marijuana wouldn’t be federally legalized, banking issues for the industry would likely persist. “This particular move by the president is particularly unpopular with Big Pharma. You see, they would much prefer to sell you pharmaceutical drugs to do far greater damage,” Stone said. “It’s really only a matter of common sense. Alcohol is probably far more damaging to the human system than cannabis, even in the full sense of marijuana, could ever be—yet alcohol sales are legal, they’re regulated and they’re taxed by the states. So why not cannabis [which is] far less damaging than oxycontin for pain?” Stone—a Republican political operative who has served as a senior campaign aide to Trump as well as to Presidents Richard Nixon and Ronald Reagan during their administrations—noted that he became a “convert” for legalization when his father was dying from cancer and cannabis “alleviated his suffering when his time came.” He’s reiterated the impact of that experience in multiple interviews over the years. “I have no qualms about my sister and I deciding to get him the cannabis that eased the final days of his life,” he said. “I hope President Trump does either reclassify, or even better, declassify cannabis—and does it now.” He also pointed out that, while “Democrats always talk about” marijuana reform, they declined to enact meaningful policy changes during prior sessions when they wielded control of both chambers of Congress and the presidency. He said that was the case under former President Barack Obama, but it was also the case under former President Joe Biden for one session—though Biden did initiate the rescheduling process that is now being considered by Trump. “They did nothing,” Stone said. “I pray that President Trump will make a very different decision.” The GOP operative also made the case for cannabis reform in an op-ed for Marijuana Moment earlier this month. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, the Republican Senate sponsor of a bipartisan cannabis banking bill said recently that Trump rescheduling marijuana would be an “important domino” to advance his legislation. Whether Trump ultimately decides to move forward with rescheduling remains to be seen. Despite his endorsement of the policy change on the campaign trail ahead of his election for a second term, he declined to restate that support when asked about it during a briefing late last month—though he did say a decision would come within weeks. Image element courtesy of Gage Skidmore. The post Trump Can Outdo Democrats By Rescheduling Marijuana When They Failed To Do So, Roger Stone Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

German officials have released a report on the impact of the nation’s marijuana legalization law, finding that fears from opponents about youth use, traffic safety and more have so far proved largely unfounded. However, the illicit market has not meaningfully diminished under the limited legal regulatory model that has been rolled out in the country to date. The interim report, which was required under the cannabis law enacted last year, assessed a series of health, public safety and economic factors associated with the end of prohibition. Among the most notable findings in the document published on Monday is the fact that youth marijuana use has continued to decline, even after possession and home cultivation were legalized for adults and social clubs offering access to members opened. Further, “no clear changes in the previous trend in cannabis consumption among adults could be observed,” the report, conducted on behalf of the federal Ministry of Health, says, according to a translation. “The percentage increase in adults who have consumed cannabis in the last 12 months, which has been observed since approximately 2011, is likely to continue…without any drastic changes,” it says. A separate recent study conducted by German federal health officials also found that rates of marijuana use declined among youth after the country legalized adult-use cannabis, contradicting one of the more common prohibitionist arguments against the reform. Another finding of the new legalization evaluation concerns traffic safety, with researchers determining that there’s been no meaningful change in incidents on the roadways associated with the policy change. “In the area of ​​road safety, partial legalization has so far shown no significant changes in self-reported driving under the influence of cannabis or in the number of people killed or injured in road traffic,” the report states. Early data on the impact of legalization on the illicit market indicates that the law has “not yet made a significant contribution to the displacement of the black market intended by the legislature,” the report found. One reason for the continued presence of the illegal market could be related to how Germany’s legalization law is being rolled out, with a limited number of social clubs that grow cannabis for members to consume—but without a comprehensive commercial industry that could provide wider access to adults. And even if broad retail launches, it may take time to substantially transition consumers to the legal market, which has been the case in Canada and U.S. states that have enacted the reform. For now, if Germany intends to substantially shift people to the legal market, “the framework for the approval and operation of cultivation associations must be simplified,” the report says. It also advises that, based on current information, there’s not a need to change the possession limit of 25 grams. “The first interim report published today confirms that the legalization of cannabis was the right and long overdue step,” MP Carmen Wegge of the Social Democratic Party (SPD) said. “The independent evaluation shows no significant increase in cannabis consumption among adults and even a decrease among minors, no noticeable negative effects on the health of adults, and significantly fewer criminal proceedings,” she said. “But the core message is clear: Partial legalization protects health and improves the ability of the constitutional state to act.” But Federal Health Minister Nina Warken, a member of the anti-legalization Christian Democratic Union, said the results so far show “worrying trends, despite the lack of further data in some areas.” “We will have to discuss possible need for action together with the coalition parties and the security authorities,” she said. Germany’s former health minister Karl Lauterbach, who spearheaded the government’s legalization plan, responded to the report, saying “cannabis consumption among young people continues to decline despite legalization.” Der Cannabiskonsum bei Jugendlichen geht trotz Legalisierung offenbar weiter zurück. Das war zu erwarten, auch andere Länder zeigen das. Wenn man den Schwarzmarkt bekämpfen will darf man Anbauclubs nicht weiter behindern. Cannabiskonsum ist kein Verbrechen https://t.co/fMPUUz2ypv — Prof. Karl Lauterbach (@Karl_Lauterbach) September 29, 2025 “That was to be expected; other countries are showing the same trend,” he said. “If one wants to combat the black market, cultivation clubs must not be further obstructed. Cannabis consumption is not a crime.” Former MP Kristine Lütke, who was one of the most vocal champions of legalization, said the report shows “there is no urgent need for action.” “Particularly encouraging: children and adolescents are not consuming cannabis more frequently than before partial legalization. The trend is rather declining,” she said. A final report on the impact of legalization in Germany is expected in April 2028. Germany’s legalization law took effect in April 2024, allowing adults to possess and grow certain amounts of cannabis and social clubs began to open, providing members with legal access to marijuana products. Following a pivotal national election earlier this year, political parties that were cooperating to form a new coalition government announced that they would be conducting an “open-ended evaluation” of the country’s marijuana legalization law—meaning that at least for now, officials will allow the policy to stay in place. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — In December, the federal minister for food and agriculture signed off on a plan to allow for research-focused commercial marijuana pilot programs to test legal and regulated access to cannabis for consumers. At the local level, the city of Frankfurt late last year announced plans to move forward with a five-year pilot program that would make cannabis products available to adults more broadly , with the city of Hanford also pursuing a similar plan. A number of other localities have also expressed interest in conducting cannabis sales pilot projects. Despite widespread concern that results of February’s election could spell doom for the legalization law, most Germans— 59 percent of eligible voters —support allowing adults to purchase cannabis from licensed stores. For the previous three years Germans were polled on the issue, support sat at just under 50 percent. But as the country’s marijuana law began being implemented last year, there was a spike in favor of the policy change. Notably, respondents who identified as CDU or CSU—two of the three coalition parties behind the new agreement—were the only political affiliations among which majorities of voters supported rolling back the reform law. German officials last year convened an international conference where leaders were invited to share their experiences with legalizing and regulating marijuana , with a focus on public health and mitigating the illicit market. Representatives from Luxembourg, Malta, the Netherlands, the Czech Republic and Switzerland were invited by German Commissioner for Addiction and Drug Issues Burkhard Blienert to the meeting in Berlin. The countries that participated in the ministerial have varying cannabis policies. Malta, for example, became the first European country to enact cannabis legalization in 2021. Luxembourg followed suit, with the reform officially taking effect in 2023 . Government officials from several countries, including the U.S., also met in Germany in 2023 to discuss international marijuana policy issues as the host nation worked to enact legalization. A group of German lawmakers, as well as Blienert, separately visited the US and toured California cannabis businesses in 2022 to inform their country’s approach to legalization. The visit came after top officials from Germany, Luxembourg, Malta and the Netherlands held their first-of-its-kind meeting to discuss plans and challenges associated with recreational marijuana legalization in 2022. The post German Government Report Shows Marijuana Legalization Hasn’t Increased Youth Use Or Traffic Accidents appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

This is the wonderful content, Cheers pertaining to supplying us this info. Preserve putting up. Buy Yamamay kuwait online

This is the wonderful content, Cheers pertaining to supplying us this info. Preserve putting up. Buy Yamamay kuwait online

A leading alcohol industry group has added a company that makes THC-infused drinks to its membership roster for the first time. Cannabuzz, a Kentucky-based manufacturer of hemp-derived THC beverages, is now an associate member of Wine & Spirits Wholesalers of America (WSWA), the company announced in a press release last week. “We’re proud to be the first THC brand to join WSWA’s THC beverage category,” Annie Rouse, Cannabuzz CEO & Founder, said in a press release. “We look forward to collaborating with the organization and providing our industry expertise to help grow a safe and accessible market.” Being a part of WSWA will give Cannabuzz “access to distributor expertise, best-practice frameworks and policy engagement as the cannabis category matures,” the company said. “Our goal isn’t just to sell drinks—it’s to help retailers, distributors, and regulators align on simple guardrails that protect consumers and give stores confidence to stock the category,” Rouse said. “We believe standardized labeling, potency appropriate serving sizes and clear age-gating will define the next chapter of adult cannabis beverages. We’re excited to join beverage-alcohol’s leading trade group to help build these responsible standards for hemp-derived THC [ready-to-drink beverages].” WSWA staff did not respond to Marijuana Moment’s request for comment for this story, though the organization’s website confirms Cannabuzz is now an associate member of the organization. The association in June called on Congress to dial back language in a House spending bill that would ban most consumable hemp products, instead proposing to maintain the legalization of naturally derived cannabinoids from the crop and only prohibit synthetic items. Members of WSWA also met with lawmakers and staffers in April to advocate for three key policy priorities that the group says is based on “sound principles of alcohol distribution.” They include banning synthetic THC, setting up a federal system for testing and labeling products and establishing state-level power to regulate retail sales. In an op-ed for Marijuana Moment in June, WSWA President and CEO Francis Creighton said echoed that point, reiterating the organization’s position that regulation is superior to prohibition. This is also consistent with WSWA’s earlier message to House and Senate Agriculture Committee last session, where the association implored congressional leaders to create a regulatory framework for hemp-based intoxicating cannabinoids—rather than impose an outright ban. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, bipartisan House lawmakers recently pushed back against attempts to ban hemp THC products, arguing that it would “deal a fatal blow” to the industry and, as currently included in a spending bill, violates congressional rules. To that end, the members say there are plans in the works to introduce an alternative measure to regulate the market. While the Senate ultimately stripped similar language from its version of the agriculture spending measure following a procedural protest from Sen. Rand Paul (R-KY), there’s still concern among stakeholders that it could wind up in the final package delivered to the president following bicameral negotiations. Dozens of hemp farmers from Kentucky also recently urged their state’s senior U.S. senator, Sen. Mitch McConnell (R-KY), to back off from his push to recriminalize some products that are derived from their crops. Paul, for his part, recently cautioned that the cannabis policy movement has “swung hard on the prohibitionist side” amid the ongoing debate over intoxicating hemp products. And he worries that, if things go awry, the hemp market could be decimated “within the next two weeks.” Asked about recent conversations with McConnell and Rep. Andy Harris (R-KY), Paul said “we’ve been working diligently” with the staff “trying to reach a compromise.” The post Major Alcohol Industry Trade Association Welcomes Its First THC Cannabis Beverage Member appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

This is such a great resource that you are providing and you give it away for free. I love seeing blog that understand the value of providing a quality resource for free. toto togel Positive site, where did u come up with the information on this posting? I'm pleased I discovered it though, ill be checking back soon to find out what additional posts you include. olxtoto I wish more authors of this type of content would take the time you did to research and write so well. I am very impressed with your vision and insight. togel 4d I am thankful to you for sharing this plethora of useful information. I found this resource utmost beneficial for me. Thanks a lot for hard work. bandar toto macau Nice to be visiting your blog again, it has been months for me. Well this article that i've been waited for so long. I need this article to complete my assignment in the college, and it has same topic with your article. Thanks, great share. koi toto

Wisconsin’s Senate president announced on Monday that she and two other bicameral Republican lawmakers have introduced legislation to legalize medical marijuana in the state. Senate President Mary Felzkowski (R), who’s previously sponsored a medical cannabis bill, said in a press release that she’s filed the new measure alongside Sen. Patrick Testin (R), with an Assembly companion version from Assemblymember Patrick Snyder (R). The text of the proposal hasn’t been posted yet, but Felzkowski’s prior bill would have allowed doctors to issue medical cannabis recommendations to patients with one of eight conditions, including cancer, seizure disorders, post-traumatic stress disorder and multiple sclerosis. The legislation was fairly restrictive, as it prohibited smokable marijuana products and wouldn’t have allowed patients to grow cannabis for personal use. Patients could have only obtained cannabis preparations in the form of oils, pills, tinctures or topicals. It’s not clear if the Senate president and her colleagues have expanded the scope of the reform for the new yet-to-be-released bill. “Someone who suffers from a serious health condition should not have to make the choice to travel to another state or break the law so they can try an alternative medicine for relief,” Felzkowski, a cancer survivor, said in a press release. “This legislation is about giving our friends, family members, and neighbors suffering from a chronic illness the freedom to explore another option with their doctor,” she said. “This is also a chance for small businesses in our state to take part in this market with reasonable regulations on making and selling these products, all while still protecting public safety.” As the 2025 session was set to get underway, the Senate leader said she was “hoping to have a conversation” in the legislature about legalizing medical marijuana this year—though the Republican Assembly speaker still represented “an obstacle,” she added. Meanwhile, a Republican candidate for governor of Wisconsin said in July that he was “open to considering different opportunities” when it comes to legalizing medical or adult-use marijuana in the state, though he has provided little in the way of specifics so far. On the Democratic side, current Gov. Tony Evers (D), who supports legalizing cannabis, will not be seeking re-election. But he said in June that if his party can take control of the legislature, the state can “finally” legalize marijuana so that residents don’t have to go to neighboring Illinois to visit its adult-use market. Separately in June, a poll from Marquette Law School found that two in three Wisconsin voters support legalizing marijuana. The survey found that support for cannabis reform has generally increased over time since the institution first started tracking public opinion on legalization in 2013, with 67 percent of voters now backing the policy change. That’s 17 percentage points higher than the 2013 results. Democrats are the most likely to favor legalizing cannabis, at 88 percent, followed by independents (79 percent). However, a majority of Republicans (56 percent) said they’re still opposed to adult-use legalization. Underscoring the importance of party control, the state’s Republican-controlled Senate and Assembly this summer rejected another attempt to legalize marijuana, defeating amendments to budget legislation that would have ended prohibition in the state and established new medical and recreational cannabis programs. Evers has routinely attempted to change that policy as part of his budget requests—and Democratic leaders have similarly pushed for reform. Republicans in the legislature also cut the marijuana provisions from a state budget proposal in May, as they’ve done in past sessions. Despite Republicans’ move to cut legalization from the budget legislation, party leaders recently acknowledged that the debate over medical marijuana legalization is “not going to go away,” and there’s hope it can be resolved this session. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — “I don’t think anyone is naive enough to think that marijuana and THC products aren’t present in the state of Wisconsin when they are readily available over state lines, so I think we need to come to an answer on this,” Assembly Majority Leader Rep. Tyler August (R) said in February. “I’m hopeful that we can.” “If we’re going to call it medical marijuana, it needs to be treated like a pharmaceutical. But the marijuana debate is going to be something that is not going to go away,” Sen. Dan Feyen (R), the assistant majority leader, said at the time. “The margins are tighter.” There have been repeated attempts to legalize medical marijuana in the legislature over recent years, including the introduction of legislation from Assembly Speaker Robin Vos (R) that called for a limited program facilitated through state-run dispensaries. That proved controversial among his Republican colleagues, however, and it ultimately stalled out last year. Evers previewed his plan to include marijuana legalization in his budget in January, while also arguing that residents of the state should be allowed to propose new laws by putting binding questions on the ballot—citing the fact that issues such as cannabis reform enjoy sizable bipartisan support while the GOP-controlled legislature has repeatedly refused to act. Previously, in 2022, the governor signed an executive order to convene a special legislative session with the specific goal of giving people the right to put citizen initiatives on the ballot, raising hopes among advocates that cannabis legalization could eventually be decided by voters. The GOP legislature did not adopt the proposal, however. Evers said in December that marijuana reform is one of several key priorities the state should pursue in the 2025 session, as lawmakers work with a budget surplus. Days after he made the remarks, a survey found the reform would be welcomed by voters in rural parts of the state. Nearly two thirds (65 percent) said they support legalizing cannabis. Last May, the governor said he was “hopeful” that the November 2024 election would lead to Democratic control of the legislature, in part because he argued it would position the state to finally legalize cannabis. “We’ve been working hard over the last five years, several budgets, to make that happen,” he said at the time. “I know we’re surrounded by states with recreational marijuana, and we’re going to continue to do it.” A Wisconsin Democratic Assemblymember tried to force a vote on a medical cannabis compromise proposal last year, as an amendment to an unrelated kratom bill, but he told Marijuana Moment he suspects leadership intentionally pulled that legislation from the agenda at the last minute to avoid a showdown on the issue. Meanwhile, the state Department of Revenue released a fiscal estimate of the economic impact of a legalization bill from then-Sen. Melissa Agard (D) in 2023, projecting that the reform would generate nearly $170 million annually in tax revenue. A legislative analysis requested by lawmakers estimated that Wisconsin residents spent more than $121 million on cannabis in Illinois alone in 2022, contributing $36 million in tax revenue to the neighboring state. Evers and other Democrats have since at least last January insisted that they would be willing to enact a modest medical marijuana program, even if they’d prefer more comprehensive reform. The post Wisconsin’s GOP Senate President Files New Medical Marijuana Legalization Bill appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Normal appointments listed here are the easiest method to thanks for the work, that means that I am going to the website daily, searching for brand new, fascinating data. Numerous, thank you! US Polo Kuwait sale online

“Well, adding a new cannabis tax into the mix now is going to tip that balance… It’s going to drive people out of the legal market.” By Jordyn Hermani, Bridge Michigan This story was originally published by Bridge Michigan, a nonprofit and nonpartisan news organization. To get regular coverage from Bridge Michigan, sign up for a free Bridge Michigan newsletter here. Michigan’s top cannabis trade association is evaluating whether to sue the state over a new marijuana tax plan that is part of a larger road and budget deal state lawmakers could finalize Tuesday. State House lawmakers last week voted 78-21 to impose a 24 percent tax on the wholesale price of marijuana sold or transferred to a retail shop, beginning January 2026. The proposal, part of a broader agreement to avoid a state government shutdown, could generate an estimated $420 million a year for road and bridge repairs, according to the nonpartisan House Fiscal Agency. But the Michigan Cannabis Industry Association is questioning whether the vote amounts to an illegal amendment to the recreational marijuana law voters approved in 2018. Under the Michigan Constitution, citizen initiatives can only be changed through three-fourths majority votes in the Legislature. The House fell five votes short of that 83-vote threshold last week. The cannabis association is consulting with attorneys, and if they feel strongly the new tax would amend the 2018 initiative, a lawsuit “would be our next step,” said Executive Director Robin Schneider. “Certainly, we don’t want to have to get there.” House Republicans maintain they’re on solid footing after consulting internally with their own legal counsel. Spokespeople for Gov. Gretchen Whitmer (D), who previously proposed a larger 32 percent wholesale tax on marijuana, did not respond to requests for comment. “It wouldn’t surprise me to see someone initiating litigation to challenge” the proposed tax, said Steve Liedel, a partner at the Lansing-based Dykema law firm who previously worked as legal counsel to then-Gov. Jennifer Granholm (D). Nonetheless “there’s precedent for the Legislature recently doing something like this,” said Liedel, pointing to a series of laws Whitmer signed in 2019 that legalized sports betting in Michigan without altering a voter-initiated gaming control law from 1996. The nearly three-decade old initiative initially established casinos and gave “authority” to the Michigan Gaming Control Board to regulate and control in-state casino gaming. Then there’s the issue of “adopt-and-amend,” said Liedel, referring to a recent Michigan Supreme Court ruling which noted a Legislature could adopt and amend a citizen-led petition initiative—so long as those actions do not occur in the same legislative session. Whether lawmakers are simply complying with legal guidance or looking for “a backdoor attempt to get around the requirement” of a three-fourths majority vote is a matter of perspective, Liedel said. “Folks are free to argue anything before the court.” Jamie Lowell, a cannabis activist who helped write the 2018 initiative, blasted last week’s vote as “completely improper and misguided” in a post to Facebook on Monday. The law already includes a 10 percent excise tax on retail marijuana sales, in addition to the state’s 6 percent sales tax. “As one of the authors of the [2018 proposal] I can attest that a wholesale tax was intentionally left out,” he wrote. The legislation is expected to go before the Michigan Senate on Tuesday. At least one no-vote is likely expected—Sen. Jeff Irwin, D-Ann Arbor, who told Bridge he believed that Michigan’s marijuana industry will take a major hit should a 24 percent wholesale tax take effect. “The secret sauce to having the legal market be successful and to drive the black market out is to have a reasonable licensing and taxation structure,” Irwin told Bridge during session Monday. “Well, adding a new cannabis tax into the mix now is going to tip that balance… It’s going to drive people out of the legal market.” That concern was shared by Schneider, head of the state Cannabis Industry Association, who noted roughly 47,000 people either directly or indirectly work in Michigan’s cannabis industry. If a wholesale tax is implemented, Schneider expressed concerns companies “are going to have to reduce their employee numbers” just to remain afloat. “After the vote tomorrow, our association’s number one focus is going to be to go back to the districts and support new candidates for every single person that voted yes” on the tax policy, she warned. The proposal won bipartisan support in the state House last week, however. Rep. Alabas Farhat, D-Dearborn, told reporters he doesn’t think marijuana companies are “doing as bad as they say they’re doing” based on the number of billboards he sees on Michigan highways. “We are heavily behind our peer states on where we ought to be on a wholesale tax,” he said, adding that Michiganders deserved to have “high quality roads that they can depend upon.” This article first appeared on Bridge Michigan and is republished here under a Creative Commons Attribution-NoDerivatives 4.0 International License. The post Michigan Marijuana Industry Group Considers Lawsuit Against Tax Hike Advancing In Legislature appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Food and Drug Administration (FDA) has updated its adverse drug event reporting forms to begin tracking incidents related to hemp-derived cannabinoid products such as CBD. The change to the federal documents—which are used by healthcare professionals, consumers and companies to report adverse experiences with drugs, cosmetics and other products—received sign-off from the White House Office of Management and Budget (OMB) earlier this month. This comes about three months after FDA posted a notice in the Federal Register advising that it would be requesting the approval for the cannabis-related change to the forms, which was first unveiled in January. The FDA change revises the “Product Type” field of safety reporting documents that are part of the agency’s MedWatch program to include a selection for “Cannabinoid Hemp Products (such as products containing CBD).” It was finalized following an initial public comment period that ended in May and a second round that closed in July. Two comments FDA received expressed support for the addition of a “cannabinoid hemp product” category “but encouraged FDA to include additional categories as well that would allow for specific data as it pertained to a wider variety of individual products,” the agency said at the time. A third called for changes to make entries easier by respondents. Also, asked in July about the widespread availability of intoxicating cannabinoid products, such as delta-8 THC, the head of FDA warned that the use of cannabinoids can lead to cardiac problems and psychosis. Meanwhile, the move to revise FDA forms 3500, 3500A and 3500B—designed to more actively gather information about adverse health effects that might be linked to hemp-derived products—comes amid a number of other CBD-focused actions at the federal level and state levels. For example, President Donald Trump on Sunday posted a video on his Truth Social platform promoting the health benefits of cannabis—suggesting that covering hemp-derived CBD under Medicare would be “the most important senior health initiative of the century.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — On Friday, bipartisan House lawmakers pushed back against attempts to ban hemp THC products, arguing that it would “deal a fatal blow” to the industry and, as currently included in a spending bill, violates congressional rules. To that end, the members said there are plans in the works to introduce an alternative measure to regulate the market. While the Senate ultimately stripped similar language from its version of the agriculture spending measure following a procedural protest from Sen. Rand Paul (R-KY), there’s still concern among stakeholders that it could wind up in the final package delivered to the president following bicameral negotiations. Democratic senators also sent a letter to leadership earlier this month that warned of the major upheaval that would happen in the hemp market if products containing any amount of THC were banned. Dozens of hemp farmers from Kentucky also recently urged their state’s senior U.S. senator, McConnell, to back off from his push to recriminalize some products that are derived from their crops. Paul, for his part, recently cautioned that the cannabis policy movement has “swung hard on the prohibitionist side” amid the ongoing debate over intoxicating hemp products. And he worries that, if things go awry, the hemp market could be decimated “within the next two weeks.” Asked about recent conversations with McConnell and Harris, Paul said “we’ve been working diligently” with the staff “trying to reach a compromise.” “A lot of the conversations have been constructive. They say, at least on the surface, they’re not trying to eliminate it—but I think we are, in some ways, talking past each other,” he said. Meanwhile, Paul recently filed a standalone bill that would go in the opposite direction of the hemp ban, proposing to triple the concentration of THC that the crop could legally contain, while addressing multiple other concerns the industry has expressed about federal regulations. The senator introduced the legislation, titled the Hemp Economic Mobilization Plan (HEMP) Act, in June. It mirrors versions he’s sponsored over the last several sessions. Harris, who championed the hemp THC ban in his chamber version of the agriculture spending legislation, told Marijuana Moment that he wasn’t concerned about any potential opposition to the hemp ban in the Senate—and he also disputed reports about the scope of what his legislation would do to the industry. The Congressional Research Service (CRS) released a report in June stating that the legislation would “effectively” prohibit hemp-derived cannabinoid products. Initially it said that such a ban would prevent the sale of CBD as well, but the CRS report was updated to exclude that language for reasons that are unclear. The hemp language is largely consistent with appropriations and agriculture legislation that was introduced, but not ultimately enacted, under the last Congress. Hemp industry stakeholders rallied against that proposal, an earlier version of which was also included in the base bill from the subcommittee last year. It’s virtually identical to a provision of the 2024 Farm Bill that was attached by a separate committee last May via an amendment from Rep. Mary Miller (R-IL), which was also not enacted into law. Photo courtesy of Kimzy Nanney. The post FDA Is Now Tracking Adverse Health Events Related To Hemp Cannabinoids Like CBD Following White House Approval appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Nice post! This is a very nice blog that I will definitively come back to more times this year! Thanks for informative post. agenolx slot login I was reading some of your content on this website and I conceive this internet site is really informative ! Keep on putting up. toto togel This is such a great resource that you are providing and you give it away for free. I love seeing blog that understand the value of providing a quality resource for free. akronoffice.com

Awesome posting, it has the such a interesting site there is listed here, keep up to date favorable deliver the results, might be backside. Discounted US Polo clothing Kuwai

DOJ agrees to delay marijuana rescheduling challenge; US man freed from Russia over cannabis to speak; OH marijuana rules changes Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Hold on, just one second before you read today’s news. Have you thought about giving some financial support to Marijuana Moment? If so, today would be a great day to contribute. We’re planning our reporting for the coming months and it would really help to know what kind of support we can count on. Check us out on Patreon and sign up to give $25/month today: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Sen. Bernie Moreno (R-OH) said if President Donald Trump follows through on marijuana rescheduling, it would “obviously” be “an important domino” toward building momentum to passing cannabis banking legislation in Congress. The Department of Justice agreed to further postpone a case challenging the administrative process behind the marijuana rescheduling proposal being considered by the Trump administration until January 27, 2026. Marc Fogel, a U.S. citizen who was jailed in Russia for possessing medical marijuana before being released through a deal reached by the Trump administration, will speak at a cannabis conference in Pennsylvania this weekend—”sharing his experience to highlight the need for compassionate, equitable policies.” The Ohio Division of Cannabis Control filed proposed changes to rules on labeling and packaging requirements for marijuana products. A new poll shows that Americans think smoking marijuana during pregnancy is not as risky as smoking cigarettes or drinking alcohol, but that only 8 percent believe it carries “low risk” or “no risk.” Erin Bass, Amy Rubenstein and Julie Vanneman of Dentons authored a new Marijuana Moment op-ed arguing that “proactive compliance” to mitigate the risks of work-related asthma in the cannabis industry “will be essential to protect workers and limit liability.” / FEDERAL The U.S. Supreme Court is considering whether to take a case on whether property owners facing marijuana-related code enforcement fines from Humboldt County, California officials have a right to a jury trial. The Drug Enforcement Administration posted another profile on one of its special agents. Rep. James Comer (R-KY) tweeted, “I’ve witnessed firsthand the tremendous potential of industrial hemp to create quality jobs & meaningful economic opportunities for American workers & family farmers. I’m leading a bipartisan effort today to protect the hemp industry.” Rep. Brian Mast (R-FL) authored a blog post touting his recent op-ed in support of marijuana rescheduling. / STATES A Pennsylvania senator tweeted, “Pennsylvania can’t afford to wait any longer. Our cannabis landscape is fractured, unregulated products are being sold in corner stores, while the illicit market continues to thrive. The time is now to establish the PA Cannabis Control Board. Let’s get this right!” Nebraska medical cannabis regulators stepped down, with one saying he felt Gov. Jim Pillen (R) sought his resignation due to his support for upholding the will of voters who enacted legalization initiatives. California officials published a report on marijuana revenue-funded youth drug prevention and treatment programs. Minnesota regulators launched a public education campaign about cannabis aimed at reaching people under the age of 25. Maryland regulators released new educational resources for cannabis cultivation and processing business employees. Washington State regulators added a new required reporting function to the state’s cannabis tracking system. The Virginia Cannabis Control Authority Board of Directors will meet on Wednesday. Colorado regulators will hold a stakeholder meeting about revisions to marijuana rules on Thursday. The New York Cannabis Control Board will meet on Monday. The U.S. Virgin Islands Cannabis Advisory Board will meet on October 8. Missouri regulators will host cannabis training sessions for police officers and government officials next month. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL Baldwin Park, California and several public officials are being ordered to pay nearly $1.9 million to a cannabis company after a jury agreed they committed fraud during the city’s licensing process. / INTERNATIONAL UK Prime Minister Keir Starmer reiterated his opposition to legalizing cannabis. / SCIENCE & HEALTH A review concluded that “cannabis-derived compounds hold promise for antiviral therapies and functional ingredients, though further research is essential to ensure safety and efficacy.” A study found that “the percentage of population agreeing with marijuana legalisation is associated with higher legislator support for drug legalisation, and presidential and legislator support for drug legalisation are associated with higher – but not more intense – citizen support for marijuana legalisation.” / ADVOCACY, OPINION & ANALYSIS The Rockefeller Institute of Government published a report on differing circuit court rulings about the federal law banning marijuana consumers from owning guns. / BUSINESS Village Farms International, Inc.’s board of directors approved a $10 million share repurchase authorization. Beverage companies sent a letter expressing concerns about Minnesota cannabis product requirements. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post Cannabis rescheduling could boost banking bill, GOP senator says (Newsletter: September 30, 2025) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thank you because you have been willing to share information with us. we will always appreciate all you have done here because I know you are very concerned with our. stylish passport holders

this really is great and also meanful. this really is great website. Relating is quite beneficial factor. you might have actually aided a lot of people which check out website and offer these usefull details. Order men's polo shirts Kuwait

This recap of the Pride & Equity Tokeativity Social 2021 really captures the vibrant energy and inclusive spirit of the event. It’s great to see how music and creativity came together to celebrate community and equity. By the way, if anyone’s interested in some fun gaming downtime inspired by unique themes, you might enjoy checking out Fnaf—it offers a different kind of excitement that’s surprisingly engaging!

Positive site, where did u come up with the information on this posting?I have read a few of the articles on your website now, and I really like your style. Thanks a million and please keep up the effective work. 신용카드현금화 Positive site, where did u come up with the information on this posting?I have read a few of the articles on your website now, and I really like your style. Thanks a million and please keep up the effective work. 먹튀검증

On the list of activities that Americans say is dangerous for pregnant women to engage in, using marijuana falls below drinking alcohol or smoking cigarettes, according to a new poll. The YouGov survey comes amid heightened attention to pregnancy-related risks after the Trump administration made a controversial assessment that linked acetaminophen, commonly known by the brand name Tylenol, to increased chances of autism for children. With respect to other substances, however, 66 percent of respondents said that using marijuana while pregnant poses a “high” health risk. Another 20 percent said there’s a “moderate risk” and 8 percent there’s either a “low” risk or no risk at all. By contrast, a total of 94 percent of Americans agree that smoking cigarettes is dangerous during pregnancy, including 84 percent who said there was a high risk. For alcohol, 96 percent said there’s either a high or moderate risk of drinking while pregnant. New polling on pregnancy risks % of U.S. adult citizens who think the following generally pose a high risk during pregnancy Cigarettes 84% Alcohol 81% Smoking marijuana 66% Exposure to pesticides 62% High stress 56% Eating raw fish 39% Taking acetaminophen 18% (Link in reply) pic.twitter.com/8T9soY4sz2 — YouGov America (@YouGovAmerica) September 26, 2025 The YouGov survey involved interviews with 2,267 U.S. adults, based on two separate 2025 polls from September 22-26 and September 23-25. The margin of error was +/-3 percentage points. The issue of cannabis use and pregnancy has been routinely debated and studied. Many experts say that marijuana shouldn’t be consumed by pregnant women, though some advocates argue that its relative harms could be outweighed in some cases by benefits in the treatment of major health conditions. In any case, advocates have pushed back against narratives that legalization adds to the risk of marijuana use during pregnancy, contending that creating regulatory models for cannabis is also a way to promote education that could inform vulnerable populations about potential risks of use. This past October, two federally funded reports published by the American Medical Association examined issues of cannabis and pregnancy. One study found that cannabis use during early pregnancy was not associated with child autism, while the other found no association with increased risk for early childhood developmental delays. Late last year, meanwhile, a report from a reproductive rights organization found that pregnancy-related prosecutions were at an all-time high in the wake of the 2022 Supreme Court decision that ended the nationwide right to abortion. By far the most common criminal allegation facing pregnant people was that they used marijuana or other drugs during their pregnancies. In Oklahoma, local news in 2022 began reporting that prosecutors there were targeting pregnant women for using medical marijuana, resulting in felony child neglect charges being filed against 26 mothers. The crime can carry up to a life prison in Oklahoma. In 2023, NIDA Director Nora Volkow blasted the criminalization of drug use by pregnant people and new parents, arguing that the resulting stigmatization is harming families and contributing to the overdose crisis. She said that families need “support, not criminalization.” Then in July of last year, a state court ruled that people cannot be prosecuted for child neglect for legally using medical marijuana while pregnant. The post Americans View Using Marijuana As Less Risky During Pregnancy Than Alcohol Or Cigarettes, Poll Finds appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Ohio regulators have filed new proposed rules to build upon the state’s marijuana legalization law, laying out plans to update regulations on labeling and packaging requirements. In a rule package that’s now open for public comment, the Department of Cannabis Control (DCC) put forward six proposals under the state’s Common Sense Initiative (CSI), which is meant to “eliminate excessive and duplicative rules and regulations that stand in the way of job creation.” One of the proposed rules would require cannabis packaging to display a “universal THC symbol” that would aim to ensure consumer and law enforcement awareness that the product contains licensed and regulated THC. Another rule would prescribe limitations on the amount of marijuana that could be sold within a given container. DCC also proposed setting requirements to ensure that certain packaging and labeling standards are met, including child-resistant materials for cannabis, before they are distributed for commercial sales. An additional rule would prevent “using a package that is attractive to children, false or misleading, obscene, a health-related statement, or encourages over consumption or intoxication, among other prohibitions.” “The rule also specifically prohibits cannabis products that reference or resemble cartoon characters, fictional characters, or pop culture icons whose target audience is children or youth,” it says. A proposed rule on single-serve products stipulates that licensed processors must abide by “certain state-required testing, packaging, and labeling requirements for raw and infused single serving units intended for direct customer sale.” A public comment period on the rule package is open until October 13. The proposal comes weeks after Ohio medical and adult-use marijuana sales officially crossed $3 billion, data from the state Department of Commerce (DOC) shows. The state sold about $703 million in recreational cannabis in the law’s first year of implementation, according to DCC data. Voters approved a ballot initiative to legalize adult-use marijuana in November 2023, and lawmakers have since taken a series of steps aimed at revising the law. However, that’s been met with pushback and the legislature has so far been unable to reach consensus to meaningfully alter the law. Last-minute disagreements between the House and Senate Republicans seemed to have derailed that plan. After taking public testimony and adopting certain changes to Senate-passed cannabis legislation, SB 56, the House Judiciary Committee ultimately declined to advance the proposal as scheduled at a June hearing, making it so the measure couldn’t advance to a floor vote. Changes approved at a hearing late in May rolled back some of the strict limits included in a version of the measure passed by the Senate in February, including a criminal prohibition on sharing marijuana between adults on private property. In March, a survey of 38 municipalities by the Ohio State University’s (OSU) Moritz College of Law found that local leaders were “unequivocally opposed” to earlier proposals that would have stripped the planned funding. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Ohio, adults as of June are able to buy more than double the amount of marijuana than they were under previous limits, with state officials determining that the market can sustainably supply both medical cannabis patients and adult consumers. Gov. Mike DeWine (R) in March separately announced his desire to reallocate marijuana tax revenue to support police training, local jails and behavioral health services. He said funding police training was a top priority, even if that wasn’t included in what voters passed in 2023. Ohio’s Senate president has also pushed back against criticism of the Senate bill, claiming the legislation does not disrespect the will of the electorate and would have little impact on products available in stores. Separately, lawmakers are considering legislation to restrict intoxicating hemp products. DeWine has repeatedly asked lawmakers to regulate or ban intoxicating hemp products such as delta-8 THC. The post Ohio Officials Post New Rules For Marijuana Packaging And Labeling Requirements As Market Expands appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Department of Justice has agreed to further postpone a case challenging the administrative process behind the marijuana rescheduling proposal being considered by the Trump administration. In a joint filing with the U.S. District Court for the Western District of Washington, DOJ and plaintiff Panacea Plant Sciences (PPS) founder and CEO David Heldreth said that, because there haven’t been any recent advancements in the broader rescheduling issue, the separate litigation related to administrative procedures should continue to be stayed through the end of the year. That is not necessarily a reflection of the status of the Trump administration’s rescheduling process. Rather, it is directly responsive to litigation over how the federal government approaches scheduling actions. The president said late last month that he would be making a decision on the overarching proposal to move marijuana to Schedule III of the Controlled Substances Act (CSA) within weeks. But for now, because the administrative hearing process remains stalled, both DOJ and PPS told the court that the stay should be kept in place until January 27, 2026, when another joint report from the parties will be due. Last January, the court approved a prior stay request for the same reasons. Then in June, the parties requested another stay that was granted, with a joint report due by Monday. This filing is the latest iteration in the case. “Because the administrative proceedings remain stayed, the parties respectfully submit that the stay continues to be warranted,” it says. “And to avoid conflicts around the holidays, the parties further propose to submit another joint status report on whether the stay continues to be warranted in the next 120 days, by January 27, 2026.” Last year, PPS’s Heldreth filed the underlying lawsuit that laid out several allegations against DEA, which he said warranted judicial intervention in the agency’s hearings on DOJ’s proposal to move cannabis from Schedule I to Schedule III of the CSA. That followed now-retired DEA Administrative Law Judge (ALJ) John Mulrooney’s prior denial of Panacea’s request to postpone rescheduling hearing over the agency’s alleged “improper blocking” of witnesses. In the original lawsuit, Heldreth had argued that the agency’s now-postponed hearing should be stayed for four main reasons, including alleged violations of a Clinton-era executive order requiring federal bodies to consult with tribal entities on rulemaking decisions that impact them, as well as the Regulatory Flexibility Act and Small Business Regulatory Enforcement Fairness Act. The fate of rescheduling remains uncertain. While Trump endorsed the reform on the campaign trail ahead of his second term, his more recent comments about an imminent decision lacked specificity and any concrete sense of whether he is still supportive of the policy change. Industry stakeholders were energized over the weekend, however, when the president shared a post on Sunday that showed a video from the pro-rescheduling Commonwealth Project touting the health benefits of hemp-derived CBD, particularly for seniors who may use it as an alternative to traditional pharmaceuticals. Meanwhile, a new poll shows that a majority of Americans don’t consider marijuana dangerous, though most do think consuming cannabis increases the likelihood that people will transition to using more dangerous drugs. The poll is one of the latest temperature checks on American sentiment toward drug policy as Trump weighs the rescheduling proposal. And while a leading prohibitionist group, Smart Approaches to Marijuana (SAM), recently claimed a poll they commissioned demonstrated majority opposition to rescheduling, a policy change that Trump endorsed on the campaign trail, the result flies in the face of multiple other national surveys showing support for reform that goes beyond rescheduling. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Another recent survey from the Coalition for Cannabis Policy, Education, and Regulation (CPEAR), which was conducted by the firm Forbes Tate Partners, showed that seven in 10 American voters want to see the end of federal marijuana prohibition—and nearly half say they’d view the Trump administration more favorably if it took action on the issue. A poll released in June that Marijuana Moment partnered on with the cannabis telehealth platform NuggMD showed that a majority of marijuana consumers disapprove of the Trump administration’s actions on cannabis policy to date, but there’s also a significant willingness among users to shift their position if the federal government opts to reschedule or legalize marijuana. Earlier this year, meanwhile, a firm associated with Trump—Fabrizio, Lee & Associates—also polled Americans on a series of broader marijuana policy issues. Notably, it found that a majority of Republicans back cannabis rescheduling—and, notably, they’re even more supportive of allowing states to legalize marijuana without federal interference compared to the average voter. Read the latest filing in the DOJ rescheduling process lawsuit below: Photo elements courtesy of rawpixel and Philip Steffan. The post DOJ Asks Federal Court To Further Delay Lawsuit On Marijuana Rescheduling Process As Trump Weighs Reform Proposal appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

An American citizen who served years in a Russian prison over marijuana possession before his release was secured by the Trump administration earlier this year will be a featured speaker at a Pennsylvania cannabis festival this coming weekend. Marc Fogel will “make his first public appearance advocating for legalization” at the 2025 Pennsylvania CannFest as state reform efforts continue to heat up in the legislature, organizers said. They’ve also invited Gov. Josh Shaprio (D), who supports legalization, to participate. Prior to his incarceration in Russia, Fogel was a registered Pennsylvania medical cannabis patient—a point repeatedly highlighted by bipartisan congressional lawmakers as they urged executive action to ensure his safe return to the U.S. The State Department under former President Joe Biden eventually designated Fogel as a “wrongfully detained” individual toward the end of his term, after previously resisting the move. The American teacher was serving a 14-year sentence after being convicted of “drug smuggling” over possession of a half-ounce of cannabis. Ahead of his designation as wrongfully detained, there were repeated calls for the diplomatic status change, including a letter sent to the Biden administration by over a dozen members of Congress that emphasized that Fogel’s access to marijuana was “necessary to subdue his pain.” “Marc’s ordeal is a stark reminder of why Pennsylvania must modernize its laws,” Trish Johnson, CFO of Zick Productions, which is organizing CannFest, said in a press release. “Governor Shapiro’s leadership is critical to ensuring no one else faces such injustice for using a substance that is legal for medical purposes here and recreationally in neighboring states.” Our blog is officially live – and we’re starting where it matters most: Marc Fogel, Governor Shapiro, and the ongoing fight for reform in PA. https://t.co/8Tn6P7q7xC — CannFest (@CannFestival) September 26, 2025 The event, which runs from October 4-5, will also feature a “Marc Fogel Lounge where patrons can enjoy the products from the festival.” This marks the 11th year of the biannual festival, which is billed as “a space where cannabis is embraced as a path to wellness, to empowerment, to connection, and to a more open-minded, compassionate future,” Zick Productions said. “The event brings together an ever-growing movement of small businesses, big brands, and visionaries who are reshaping how we understand health and personal freedom—reminding us that progress requires people standing together for something better,” the company said. “With this event, we hope to draw those people to Berks County, all while supporting the local economy with lodging, dining, and shopping.” Reminiscent of Fogel’s experience, Brittney Griner—a U.S. professional basketball player who was previously incarcerated in Russia over possession of marijuana—was also set to attend a cannabis advocacy event earlier this year. But she ultimately pulled out after discovering what she felt was a threatening message in her hotel room. In Pennsylvania, the years-long debate in the legislature over moving forward with adult-use legalization continues. Recently, a top aide to the governor said lawmakers should stop introducing new competing marijuana legalization bills and instead focus on building consensus on the issue—but emphasized that any measure that advances needs to contain equity provisions if Shapiro is going to sign it into law. Sen. Dan Laughlin (R), who serves as chair of the Senate Law and Justice Committee, said last month that the House “needs to pass the language in my [legalization] bill and send it to my committee” after which point he “can negotiate with the Senate and the governor.” The Democratic-controlled House, however, has already advanced a legalization proposal this session that called for a state-run sales model. That measure was quickly quashed in Laughlin’s Senate committee, however, with the GOP lawmaker and others insisting that a more traditional approach of licensing privates businesses would have a better shot. Laughlin separately said recently that supporters are “picking up votes” to enact the reform this session. Shapiro, for his part, said last month that he won’t “concede” on his plan to legalize adult-use cannabis through the budget. Meanwhile, the leading Republican candidate in the race to become the next governor of Pennsylvania dodged a question about her stance on legalizing marijuana—saying she doesn’t have a “policy position” on the issue and arguing that the sitting governor’s proposal for reform “way, way overstated” potential revenue. The candidate, Pennsylvania Treasurer Stacy Garrity (R), pointed to neighboring Ohio, which launched its own adult-use cannabis market this year, saying “they generated about $115 million in revenue.” And while the populations of both states are relatively comparable, Shapiro’s budget projected $536.5 million in cannabis revenue in the first fiscal year of implementation. She did, however, say that if Pennsylvania moves forward on enacting the reform, she’ll “make sure that it’s banked appropriately.” Meanwhile, a Pennsylvania Democratic senator recently said that federal marijuana rescheduling—which Trump said he’d be making a decision on imminently—would be “very influential” in advancing legalization in his state, giving “political cover” to GOP members on the fence about reform. Sen. Sharif Street (D) discussed the status of cannabis legalization efforts in the Keystone State, including a bipartisan proposal to end prohibition that he filed alongside Laughlin in July. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — The legalization bill with a state-run sales model that passed the House isn’t necessarily dead for the session as a vehicle to advance reform, however. And Democrats in the chamber recently called on voters to pressure state senators to sign off on the cannabis measure, arguing that it would benefit health and safety and bring in billions of dollars in revenue for the commonwealth. Polls have shown bipartisan support for legalization among voters, but the reform has consistently stalled in the legislature, due largely to GOP opposition. But not all Republican members are against the policy change—and one recently said she felt her party should seize the “opportunity to snatch” the issue from Democrats. In addition to pushback from Senate Majority Leader Pittman, another Republican, Sen. Scott Martin, who chairs the influential Appropriations Committee, said earlier this month that he didn’t plan to move on any adult-use legalization bills. Separately, just days after Laughlin and Street filed their measure, Reps. Emily Kinkead (D) and Abby Major (R)—alongside eight other cosponsors—filed legislation in the House to enact the reform. The pair have previously championed other proposals to end prohibition. Laughlin and 16 other lawmakers also recently filed a separate bill to create a new regulatory body in the state that would begin overseeing medical cannabis while preparing to eventually handle the adult-use market as well. Separately, a recent poll found that Pennsylvania voters say they favor a model where cannabis is sold by licensed private businesses rather than through a system of state-run stores. Meanwhile, a Democratic lawmaker recently filed a bill that seeks to require employers to cover the costs of medical cannabis for qualifying patients receiving workers’ compensation. Photo courtesy of Philip Steffan. The post American Who Was Jailed In Russia For Medical Marijuana To Speak At Pro-Legalization Event After Being Freed By Trump Admin Deal appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“The cannabis industry’s unique exposures and the documented health concerns are likely to accelerate regulatory action and litigation risk.” By Erin Bass, Amy Rubenstein and Julie Vanneman, Dentons The legal cannabis industry employs more than 440,000 full-time workers across the United States (not including hemp industry employees). As legalization spreads, so do regulatory and workplace safety challenges. A recent multi-state study led by public health agencies in California, Massachusetts, Michigan and Washington, and supported by the National Institute for Occupational Safety and Health (NIOSH), provides the most comprehensive look yet at work-related asthma in the cannabis sector. The findings highlight evolving health concerns, and that cannabis operators should review their safety and compliance measures. What the Data Show: Exposures and Evolving Health Concerns From the time of legalization in each state through 2023, 30 confirmed cases of work-related asthma were identified among cannabis industry workers. Most cases involved young (ages 18-34), male workers, in indoor cultivation or processing roles. Notably, two fatalities were directly linked to occupational asthma in cannabis facilities. The most frequently reported exposures were: Cannabis plant dust and marijuana plant material (by far the majority of reported cases); Mold and other microorganisms; Cleaning and disinfecting products (notably those containing hydrogen peroxide, peracetic acid or bleach); and Physical factors (humidity, heat, cold). Most cases occurred within the first three years of employment, and half developed symptoms within the first year. In all cases, there was a relationship between symptoms and work, where symptoms increased with workplace exposure and decreased without it. Regulatory and Legal Implications: OSHA, Workers’ Compensation and Beyond The study’s findings have immediate compliance implications for cannabis operators. First, rising case numbers could drive increased Occupational Safety and Health Administration (OSHA) and state-level attention. While cannabis operators are familiar with oversight from state cannabis compliance agencies, it is crucial for them to recognize that they also face regulatory scrutiny from occupational safety and health agencies. The new report emphasizes the importance of acknowledging the well-known hierarchy of occupational safety and health controls and implementing appropriate responses in the cannabis context. The most effective control is elimination. While it is impossible to eliminate any hazards from cannabis itself, it is possible to eliminate certain other hazards, such as exposure to particularly concerning disinfectants, and to minimize exposure to mold. Further, a job hazard analysis could identify processes that generate high levels of dust and prioritize interventions accordingly. The next step in the hierarchy of controls is engineering controls, including steps such as installing local exhaust ventilation and HEPA filtration. Administrative controls are next. In this context, procedures could be adjusted to limit personnel access to high-dust areas and provide education on the potential hazards of cannabis dust. Finally, personal protective equipment (PPE) could be deployed. Initiatives to require respirators could be considered during or after the implementation of engineering controls. Further, medical surveillance programs could identify symptoms early and provide for job reassignment or medical removal as needed. Regulators are expected to scrutinize respiratory hazard controls, training and medical surveillance programs in light of the findings. Second, workers’ compensation programs could be impacted. Only about half of affected workers filed claims, and half of those were denied—often due to insufficient clinical documentation or under-recognition of the cannabis industry’s particular hazards. Employers should anticipate more claims and potential litigation as awareness grows. Third, employers must consider their obligations to provide reasonable accommodations under the Americans with Disabilities Act (ADA) and state law analogs. A cannabis allergy may qualify as a “disability” under the ADA. Thus, if an employee presents with a cannabis allergy that impacts her ability to perform her job, an employer has a duty to engage in the interactive process with the employee to determine if there are reasonable accommodations that would enable the employee to perform the essential functions of her job. Potential accommodations could include providing the employee with PPE or transferring the employee to another position. These inter-related issues may appear all at once for a cannabis employer. For example, an employee with concerns about work-related asthma could file a workers’ compensation claim, seek an accommodation in the workplace and submit a complaint to OSHA. Even if the employer promptly offered a reasonable accommodation that was acceptable to the employee, such as transfer to a different position, OSHA could still decide to investigate. A citation resulting from the investigation could include a call for abatement measures that involve workplace changes beyond those already implemented in response to one employee’s complaint. Practical Steps for Cannabis Operators Effective compliance and risk mitigation strategies can prevent or help minimize employer liability and can positively impact employee health outcomes. Operators and associated parties should consider the following practical steps summarized below. Conduct a Job Hazard Analysis: Identify high-risk tasks (e.g., grinding, trimming, cleaning) and prioritize controls. Upgrade Ventilation and Dust Controls: Install local exhaust and HEPA filtration in processing areas. Review and Substitute Cleaning Chemicals: Avoid asthma-sensitizing disinfectants where possible. Implement Comprehensive Training: Educate workers on respiratory hazards, symptom recognition and reporting procedures. Establish Medical Surveillance: Partner with occupational health providers to monitor for early signs of work-related asthma. Document and Respond to Incidents: Maintain detailed records of exposures, symptoms and corrective actions. Looking Ahead: Heightened Scrutiny and Evolving Standards The cannabis industry’s unique exposures and the documented health concerns are likely to accelerate regulatory action and litigation risk. Proactive compliance—mirroring best practices in other high-risk industries—will be essential to protect workers and limit liability. Early recognition and intervention, robust hazard controls and a strong safety culture are critical to preventing work-related asthma and ensuring the long-term health and productivity of the cannabis workforce. As with many other emerging regulatory issues these bellwether cases may predict a trend in occupational health. Erin Bass is a partner in Dentons US LLP’s Employment and Labor practice. Amy Rubenstein is a partner in the Health Care practice. Julie Vanneman is a shareholder in Dentons Cohen & Grigsby’s Environmental practice. The post What Cannabis Companies Need To Know About Work-Related Asthma (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Great Publish, I'm a large believer within publishing remarks upon websites in order to allow weblog authors realize that they’ve additional some thing beneficial in order to the internet! 1xbet promo code free spins

Ones new music is usually wonderful. You could have many incredibly proficient painters. When i hope people the most beneficial connected with achievements. 1xbet promo code today bd

Many thanks with regard to supplying current improvements concerning the issue, We anticipate study much more. 1xbet free promo code today